{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:53:32Z","timestamp":1791406412886,"version":"4.3.3"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>In the present study, we investigated the effect of two doses of atropine eye drops versus placebo on myopia progression in children and adolescents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this double-blind, randomized clinical trial, 67 patients aged 6 to 18 years with myopia of -2 to -6 D were enrolled and randomized to receive a placebo eye drop, atropine 0.1%, or 0.01% ophthalmic solution (one drop per night for 6 months). All participants were followed-up with for one year after the beginning of the study (at zero, one, three, six, and 12 months) and their spherical equivalent (SE), axial length (AL), anterior chamber depth (ACD), and far and near visual acuity (VA) and the eye drops side effects were recorded. A comparison among the groups was performed using SPSS software, version 24.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Spherical equivalent, AL, and ACD decreased and far VA improved in atropine groups to a greater extent than the placebo group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .05) at the 6-month follow-up. The most common side effects of atropine 0.1% eye drop included photophobia and decreased near VA. At the end of the study (six months after the cessation of atropine), a rebound effect was observed; this effect was especially severe in the 0.1% atropine group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Atropine eye drops are effective for slowing down and preventing myopia progression. However, without long-term treatment, they will have a rebound effect. A lower dose (0.01%) is suggested for reducing the side effects and rebound effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijpvm.ijpvm_175_22","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T08:34:09Z","timestamp":1716885249000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["The Preventive Role of Atropine Eye Drops on Myopia Progression: A Double-Blind Randomized Clinical Trial"],"prefix":"10.4103","volume":"14","author":[{"given":"Abdolreza","family":"Medghalchi","sequence":"first","affiliation":[{"name":"Department of Eye, Eye Research Center, Amiralmomenin Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Behboudi","sequence":"additional","affiliation":[{"name":"Department of Eye, Eye Research Center, Amiralmomenin Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Akbari","sequence":"additional","affiliation":[{"name":"Department of Eye, Eye Research Center, Amiralmomenin Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza Soltani","family":"Moghadam","sequence":"additional","affiliation":[{"name":"Department of Eye, Eye Research Center, Amiralmomenin Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Kazemnejad","sequence":"additional","affiliation":[{"name":"Department of Eye, Eye Research Center, Amiralmomenin Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah","family":"Sabnan","sequence":"additional","affiliation":[{"name":"Department of Eye, Eye Research Center, Amiralmomenin Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4]]},"reference":[{"key":"R1-20241021","first-page":"693","article-title":"Refractive errors: Epidemiology, effects and treatment options","volume":"113","author":"Schiefer","year":"2016","journal-title":"Dtsch Arztebl Int"},{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/bjophthalmol-2011-300539","article-title":"Global estimates of visual impairment: 2010","volume":"96","author":"Pascolini","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"R3-20241021","first-page":"35","article-title":"Myopia: A growing global problem with sight-threatening complications","volume":"28","author":"Holden","year":"2015","journal-title":"Community Eye Health"},{"key":"R4-20241021","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/OPX.0000000000000516","article-title":"The age-specific prevalence of myopia in Asia: A meta-analysis","volume":"92","author":"C-W","year":"2015","journal-title":"Optom Vis Sci"},{"key":"R6-20241021","first-page":"5","article-title":"High myopia and its risks","volume":"32","author":"Williams","year":"2019","journal-title":"Community Eye Health"},{"key":"R7-20241021","first-page":"179","article-title":"Current status on the development and treatment of myopia","volume":"83","author":"Cooper","year":"2012","journal-title":"Optometry"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/ICL.0000000000000499","article-title":"A review of current concepts of the etiology and treatment of myopia","volume":"44","author":"Cooper","year":"2018","journal-title":"Eye Contact Lens"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/ICL.0b013e318296792c","article-title":"Long-term contact lens wear of children and teens","volume":"39","author":"Walline","year":"2013","journal-title":"Eye Contact Lens"},{"key":"R10-20241021","first-page":"CD004916","article-title":"Interventions to slow progression of myopia in children","volume":"1","author":"Walline","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/ICL.0000000000000677","article-title":"Biological mechanisms of atropine control of myopia","volume":"46","author":"Upadhyay","year":"2020","journal-title":"Eye Contact Lens"},{"key":"R12-20241021","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.ophtha.2012.05.014","article-title":"Atropine dose to treat myopia","volume":"119","author":"Galvis","year":"2012","journal-title":"Ophthalmology"},{"key":"R13-20241021","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1021\/pr500558y","article-title":"Involvement of GABA transporters in atropine-treated myopic retina as revealed by iTRAQ quantitative proteomics","volume":"13","author":"Barathi","year":"2014","journal-title":"J Proteome Res"},{"key":"R14-20241021","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/bjo.2004.045526","article-title":"Multifocal electroretinogram in children on atropine treatment for myopia","volume":"89","author":"Luu","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R15-20241021","doi-asserted-by":"crossref","first-page":"176","DOI":"10.7150\/ijms.39365","article-title":"Efficacy and safety of 1% atropine on retardation of moderate myopia progression in chinese school children","volume":"17","author":"Zhu","year":"2020","journal-title":"Int J Med Sci"},{"key":"R16-20241021","first-page":"78","article-title":"Topical atropine in the control of myopia","volume":"5","author":"Galvis","year":"2016","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"R17-20241021","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: Safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2)","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"key":"R18-20241021","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","article-title":"Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: Phase 2 report","volume":"127","author":"Yam","year":"2020","journal-title":"Ophthalmology"},{"key":"R19-20241021","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ajo.2013.09.020","article-title":"Atropine for the treatment of childhood myopia: Changes after stopping atropine 0.01%, 0.1% and 0.5%","volume":"157","author":"Chia","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R20-20241021","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ophtha.2015.10.012","article-title":"An important step forward in myopia prevention: Low-dose atropine","volume":"123","author":"Morgan","year":"2016","journal-title":"Ophthalmology"},{"key":"R21-20241021","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41433-018-0139-7","article-title":"Update in myopia and treatment strategy of atropine use in myopia control","volume":"33","author":"P-C","year":"2019","journal-title":"Eye (Lond)"},{"key":"R22-20241021","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.ophtha.2017.05.032","article-title":"Atropine for the prevention of myopia progression in children: A report by the American Academy of Ophthalmology","volume":"124","author":"Pineles","year":"2017","journal-title":"Ophthalmology"},{"key":"R23-20241021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-00923-1","article-title":"A multicenter Spanish study of atropine 0.01% in childhood myopia progression","volume":"11","author":"P\u00e9rez-Flores","year":"2021","journal-title":"Sci Rep"},{"key":"R24-20241021","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","article-title":"Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: A randomized clinical trial","volume":"138","author":"Wei","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"R25-20241021","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/jop.2015.0043","article-title":"Atropine 0.01% eyedrops significantly reduce the progression of childhood myopia","volume":"31","author":"Clark","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"R26-20241021","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-year clinical trial on atropine for the treatment of myopia 2: Myopia control with atropine 0.01% eyedrops","volume":"123","author":"Chia","year":"2016","journal-title":"Ophthalmology"}],"container-title":["International Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpvm.ijpvm_175_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:43:16Z","timestamp":1787067796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpvm.ijpvm_175_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijpvm.ijpvm_175_22","relation":{},"ISSN":["2008-7802","2008-8213"],"issn-type":[{"value":"2008-7802","type":"print"},{"value":"2008-8213","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"2022-05-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}